Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Murphy (Princeton, United States of America), C. Sum (Princeton, United States of America), T. Wang (Princeton, United States of America), R. Heiry (Princeton, United States of America), S. Kalinowski (Princeton, United States of America), C. Hung (Princeton, United States of America), C. Chu (Princeton, United States of America), A. Azzara (Princeton, United States of America), Z. Milinda (Princeton, United States of America), L. Burns (Princeton, United States of America), B. Zinker (Princeton, United States of America), S. Boehm (Princeton, United States of America), J. Taylor (Princeton, United States of America), J. Sapuppo (Princeton, United States of America), M. Kathy (Princeton, United States of America), C. Mary-Ellen (Princeton, United States of America), R. Kaltenbach (Princeton, United States of America), S. Dhanusu (Princeton, United States of America), S. Tao (Princeton, United States of America), H. Zhang (Princeton, United States of America), L. Kennedy (Princeton, United States of America), J. Shi (Princeton, United States of America), J. Li (Princeton, United States of America), S. Walker (Princeton, United States of America), Y. Shi (Princeton, United States of America), Y. Wang (Princeton, United States of America), R. Reddigunta (Princeton, United States of America), R. Jeffrey (Princeton, United States of America), B. Ellsworth (Princeton, United States of America), D. Gordon (Princeton, United States of America), M. Soars (Princeton, United States of America), M. Gill (Princeton, United States of America), P. Cheng (Princeton, United States of America). LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation. 5383

Member's Comments

No comment yet.

Related content which might interest you: LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Effects of a TRPV4 antagonist and pirfenidone on idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 Calcium-sensing receptor as a therapeutic target for pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Late Breaking Abstract: Anti-fibrogenic effects of the endothelin-A receptor antagonist ambrisentan in a mouse pulmonary fibrosis model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Transcriptome profiling reveals a potential role for antagonism of the calcium-sensing receptor in the prophylaxis of idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Blocking endothelin: breaking new ground Source: Eur Respir Rev 2008; 17: 24-29 Year: 2007 Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 In vitro modelling of epithelia-fibroblast interactions in idiopathic pulmonary fibrosis Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019